我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
289
47 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
10
3.5%
已完成
155
53.6%
Enrolling By Invitation
14
4.8%
尚未招募
23
8.0%
招募中
35
12.1%
终止
6
2.1%
Unknown
41
14.2%
撤回
5
1.7%
暂无批准数据
- A new clinical trial is investigating tirzepatide's effects on brown adipose tissue activity and volume in adults with obesity, using advanced imaging techniques including 18F-FDG-PET/CT, MRI, and infrared thermography over 24 weeks. - Cochrane review evidence confirms tirzepatide likely results in significant weight loss in the medium term (up to 1.5 years) and maintains this effect long-term (around 3.5 years) compared to placebo. - The drug may increase non-serious side effects but shows little difference in serious adverse events, with potential benefits for thermogenic energy expenditure through novel mechanisms beyond caloric restriction.
